TY - JOUR
T1 - Temporal changes in FFRCT-Guided Management of Coronary Artery Disease – Lessons from the ADVANCE Registry
AU - Nous, Fay
AU - Budde, Ricardo P.J.
AU - Fairbairn, Timothy A.
AU - Akasaka, Takashi
AU - Nørgaard, Bjarne L.
AU - Berman, Daniel S.
AU - Raff, Gilbert
AU - Hurwitz-Koweek, Lynne M.
AU - Pontone, Gianluca
AU - Kawasaki, Tomohiro
AU - Sand, Niels Peter R.
AU - Jensen, Jesper M.
AU - Amano, Tetsuya
AU - Poon, Michael
AU - Øvrehus, Kristian A.
AU - Sonck, Jeroen
AU - Rabbat, Mark G.
AU - Mullen, Sarah
AU - De Bruyne, Bernard
AU - Rogers, Campbell
AU - Matsuo, Hitoshi
AU - Bax, Jeroen J.
AU - Leipsic, Jonathon
AU - Patel, Manesh R.
AU - Nieman, Koen
N1 - Funding Information:
Dr. Nous has received travel sponsorship from HeartFlow. Dr. Fairbairn has served on the Speakers Bureau for HeartFlow. Dr. Nørgaard has received unrestricted institutional research grants from Siemens and HeartFlow. Dr. Berman has received unrestricted research support from HeartFlow. Dr. Hurwitz-Koweek has received research support and fee as speaker from HeartFlow and Siemens . Dr. Pontone has received research grant and/or fee as speaker from GE Healthcare , Bracco, and HeartFlow. Dr. Budde has institutional research support from HeartFlow and Siemens Healthineers . Dr. Sonck has received research grant support from the Cardiopath PhD program. Dr. Rabbat has served as a consultant for HeartFlow. Dr. Mullen is an employee of and owns equity in HeartFlow. Dr. De Bruyne has received consulting fees from Abbott , Opsens, and Boston Scientific; and is a shareholder for Siemens , GE Healthcare , Bayer , Philips , HeartFlow, Edwards Lifesciences , and Sanofi . Dr. Rogers is employee of and owns equity in HeartFlow. Dr. Leipsic has served as a consultant for and owns stock options in Circle CVI and HeartFlow. Dr. Patel has received research grants from HeartFlow, Bayer , Janssen, and the National Heart, Lung, and Blood Institute; and has served on the advisory board for HeartFlow, Bayer , and Janssen. Dr. Nieman has received institutional research support from Siemens Healthineers , HeartFlow, GE Healthcare , and Bayer Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 Society of Cardiovascular Computed Tomography
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: The ADVANCE registry is a large prospective study of outcomes and resource utilization in patients undergoing coronary computed tomography angiography (CCTA) and CT-based fractional flow reserve (FFRCT). As experience with new technologies and practices develops over time, we investigated temporal changes in the use of FFRCT within the ADVANCE registry. Methods: 5083 patients with coronary artery disease (CAD) on CCTA were prospectively enrolled in the ADVANCE registry and were divided into 3 equally sized cohorts based on the temporal order of enrollment per site. Demographics, CCTA and FFRCT findings, and clinical outcomes through 1-year follow-up, were recorded and compared between tertiles. Results: The number of patients with a ≥70% stenosis on CCTA was similar over time (33.6%, 30.9%, and 33.8% for cohort 1–3). The rate of positive FFRCT ≤0.80 was higher for cohorts 2 (67.3%) and 3 (74.6%) than for cohort 1 (57.1%, p < 0.001). Invasive FFR rates decreased from 25.8% to 22.4% between cohort 1 and 3 (p = 0.023). Moreover, patients with a FFRCT ≤0.80 were less frequently referred for invasive coronary angiography (ICA) (from 62.9% to 52.9%, p < 0.001), and underwent fewer revascularizations between cohort 1 and 3 (from 41.9% to 32.0%, p < 0.001). The prevalence of major events was low (1.2%) and similar between cohorts. Conclusions: Growing experience with FFRCT improved the likelihood of identifying hemodynamically significant CAD and safely reduced the need for ICA and revascularization in patients with anatomically significant disease even in the instance of an abnormal FFRCT.
AB - Background: The ADVANCE registry is a large prospective study of outcomes and resource utilization in patients undergoing coronary computed tomography angiography (CCTA) and CT-based fractional flow reserve (FFRCT). As experience with new technologies and practices develops over time, we investigated temporal changes in the use of FFRCT within the ADVANCE registry. Methods: 5083 patients with coronary artery disease (CAD) on CCTA were prospectively enrolled in the ADVANCE registry and were divided into 3 equally sized cohorts based on the temporal order of enrollment per site. Demographics, CCTA and FFRCT findings, and clinical outcomes through 1-year follow-up, were recorded and compared between tertiles. Results: The number of patients with a ≥70% stenosis on CCTA was similar over time (33.6%, 30.9%, and 33.8% for cohort 1–3). The rate of positive FFRCT ≤0.80 was higher for cohorts 2 (67.3%) and 3 (74.6%) than for cohort 1 (57.1%, p < 0.001). Invasive FFR rates decreased from 25.8% to 22.4% between cohort 1 and 3 (p = 0.023). Moreover, patients with a FFRCT ≤0.80 were less frequently referred for invasive coronary angiography (ICA) (from 62.9% to 52.9%, p < 0.001), and underwent fewer revascularizations between cohort 1 and 3 (from 41.9% to 32.0%, p < 0.001). The prevalence of major events was low (1.2%) and similar between cohorts. Conclusions: Growing experience with FFRCT improved the likelihood of identifying hemodynamically significant CAD and safely reduced the need for ICA and revascularization in patients with anatomically significant disease even in the instance of an abnormal FFRCT.
KW - Angina
KW - Computerized tomography
KW - Coronary artery disease
KW - Fractional flow reserve
KW - Ischemia
UR - http://www.scopus.com/inward/record.url?scp=85085133776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085133776&partnerID=8YFLogxK
U2 - 10.1016/j.jcct.2020.04.011
DO - 10.1016/j.jcct.2020.04.011
M3 - Article
C2 - 32418861
AN - SCOPUS:85085133776
JO - Journal of Cardiovascular Computed Tomography
JF - Journal of Cardiovascular Computed Tomography
SN - 1934-5925
ER -